Abstract:<p></p><p>Phosphodiesterases(PDEs) are vital in signal transduction, specificallyby hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notablefor its prominence in the striatum and its regulatory function overneurotransmitters in medium-spiny neurons. Given the dopamine deficiencyin Parkinson’s disease (PD) that affects striatal pathways,PDE10A inhibitors could offer therapeutic benefits by modulating D1and D2 receptor signaling. This study was motivated by the successfulhistory of quinazoline/quinazoline scaffolds in the inhibition ofPDE10A. This study involved detailed in silico evaluationsthrough docking followed by pharmacological, pharmacophoric, and pharmacokineticanalyses, prioritizing central nervous system (CNS)-active drug criteria.Seven cyclic peptides, those featuring the quinazoline/quinazolinemoiety at both termini, exhibited notably enhanced docking scorescompared to those of the remaining alkaloids within the screened library.We identified 7 quinolines and 1 quinazoline including Lepadin G,Aspernigerin, CJ-13536, Aurachin A, 2-Undecyl-4(1H)-quinolone, Huajiaosimuline 3-Prenyl-4-prenyloxyquinolin-2-one,and Isaindigotone that followed the standard CNS active drug criteria.The dominant quinoline ring in our study and its related quinazolinewere central to our evaluations; therefore, the pharmacophoric featuresof these scaffolds were highlighted. The top alkaloids met all CNS-activedrug properties; while nonmutagenic and without PAINS alerts, manyindicated potential hepatotoxicity. Among the compounds, Huajiaosimulinewas particularly significant due to its alignment with lead-likenessand CNS-active criteria. Aspernigerin demonstrated its affinity fornumerous dopamine receptors, which signifies its potential to alterdopaminergic neurotransmission that is directly related to PD. Interestingly,the majority of these alkaloids had biological targets primarily associatedwith G protein-coupled receptors, critical in PD pathophysiology.They exhibit superior excretion parameters and toxicity end-pointscompared to the standard. Notably, selected alkaloids demonstratedstability in the binding pocket of PDE10A according to the moleculardynamic simulation results. Our findings emphasize the potential ofthese alkaloids as PDE10A inhibitors. Further experimental studiesmay be necessary to confirm their actual potency in inhibiting PDE10Abefore exploring their therapeutic potential in PD.</p>

Quassinoids from Twigs of Harrisonia perforata (Blanco) Merr and Their Anti-Parkinson’s Disease Effect

Haperforatones A-M, thirteen undescribed limonoids from Harrisonia perforata with anti-inflammatory activity

Quassinoids from the Roots of Eurycoma longifolia and Their Anti-Proliferation Activities

Quassinoids from the Root Barks of Ailanthus altissima : Isolation, Configurational Assignment, and Cytotoxic Activities

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson’s Disease through a Computational Approach

Polyphenolic glycosides with unusual four-membered ring possessing anti-Parkinson's disease potential from black wolfberry

Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models

Fungal Coculture of Herpotrichia sp. and Trametes versicolor Induces Production of Diverse Metabolites with Anti-Parkinson's Neuroprotective Activity

Quassinoids with Inhibitory Activities against Plant Fungal Pathogens from Picrasma javanica

New di-spirocyclic labdane diterpenoids from the aerial parts of Leonurus japonicus

Meroterpenoids from a Medicinal Fungus Antrodia cinnamomea

Discovery of Resorcinol-Based Polycyclic Structures As Tyrosinase Inhibitors for Treatment of Parkinson's Disease

Design, Synthesis, and Examination of Neuron Protective Properties of Alkenylated and Amidated Dehydro-Silybin Derivatives

Quassinoids and Alkaloids from the Stems of Picrasma Quassioides with Nitric Oxide Inhibitory Activity

Polyprenylated xanthones with potential anti-inflammatory and anti-HIV effects from the stems and leaves of Cratoxylum cochinchinense (Lour.) Blume

Aromatic monoterpenoid glycosides from rattan stems of Schisandra chinensis and their neuroprotective activities

Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease

New sesquiterpenoids with neuroprotective effects in vitro and in vivo from the Picrasma chinensis

New Resorcinol Derivatives from a Sponge‐Derived Fungus Hansfordia Sinuosae

Structurally Diverse Sesquiterpenoid Glycoside Esters from Pittosporum qinlingense with Anti-neuroinflammatory Activity

6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatment